Monaco Asset Management SAM Invests $610,000 in Inogen, Inc. (NASDAQ:INGN)

Monaco Asset Management SAM acquired a new position in Inogen, Inc. (NASDAQ:INGN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 75,000 shares of the medical technology company’s stock, valued at approximately $610,000.

Several other large investors have also recently modified their holdings of INGN. Jump Financial LLC grew its holdings in shares of Inogen by 153.0% during the 4th quarter. Jump Financial LLC now owns 39,728 shares of the medical technology company’s stock worth $218,000 after acquiring an additional 24,028 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Inogen during the 4th quarter worth approximately $189,000. Olympiad Research LP purchased a new position in shares of Inogen during the 4th quarter worth approximately $97,000. PNC Financial Services Group Inc. grew its holdings in shares of Inogen by 2,918.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 7,646 shares during the period. Finally, Quadrature Capital Ltd grew its holdings in shares of Inogen by 106.4% during the 4th quarter. Quadrature Capital Ltd now owns 31,071 shares of the medical technology company’s stock worth $171,000 after acquiring an additional 16,017 shares during the period. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Price Performance

NASDAQ:INGN opened at $11.33 on Tuesday. The firm has a market capitalization of $268.75 million, a price-to-earnings ratio of -2.73 and a beta of 1.05. Inogen, Inc. has a one year low of $4.13 and a one year high of $13.33. The business has a fifty day moving average price of $10.44 and a 200-day moving average price of $8.65.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical technology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.31. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The business had revenue of $88.77 million during the quarter, compared to analyst estimates of $82.50 million. During the same quarter in the prior year, the business posted ($0.42) EPS. Inogen’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, equities research analysts expect that Inogen, Inc. will post -1.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

INGN has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. StockNews.com raised Inogen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Inogen has an average rating of “Hold” and an average price target of $7.00.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.